CanSino Biologics proposes new share, option schemes for employee incentives

CanSino Biologics Inc. announced on September 26, 2025, a proposal for a 2025 A Share Incentive Scheme and a 2025 H Share Option Scheme, alongside the immediate grant of H share options to core management. The A Share Incentive Scheme proposes granting up to 2,580,000 Restricted Shares, representing approximately 1.04% of the total issued share capital, with a grant price of RMB41.20 per A Share.

Under the H Share Option Scheme, 860,000 Options are proposed for grant, with 371,300 Options for dr. Xuefeng YU requiring independent shareholder approval. The exercise price for these H Share Options is HK$49.924 per H Share. Both schemes are designed to motivate core management and employees, aligning their performance with the company’s strategic objectives and long-term development.

The company also plans to cancel 406,098 repurchased A Shares, reducing the registered capital by RMB406,098. These proposals will be put to shareholders for approval at an upcoming Extraordinary General Meeting.